

Barthelmes Daniel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4996174/publications.pdf>

Version: 2024-02-01

88
papers

2,292
citations

279487

23
h-index

243296

44
g-index

89
all docs

89
docs citations

89
times ranked

2244
citing authors

#	ARTICLE	IF	CITATIONS
1	Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry. British Journal of Ophthalmology, 2023, 107, 842-848.	2.1	3
2	Longer treatment intervals are associated with reduced treatment persistence in neovascular age related macular degeneration. Eye, 2023, 37, 467-473.	1.1	4
3	Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion. Eye, 2023, 37, 1145-1154.	1.1	3
4	Initial observation or treatment for diabetic macular oedema with good visual acuity: two-year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry. Acta Ophthalmologica, 2022, 100, 285-294.	0.6	3
5	THE IMPACT OF DISEASE ACTIVITY ON 5-YEAR OUTCOMES IN PATIENTS UNDERGOING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2022, 42, 95-106.	1.0	6
6	12-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry. Acta Ophthalmologica, 2022, 100, .	0.6	7
7	Assessing Choroidal Nevi, Melanomas and Indeterminate Melanocytic Lesions Using Multimodal Imaging—A Retrospective Chart Review. Current Oncology, 2022, 29, 1018-1028.	0.9	5
8	Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry. Ophthalmology and Therapy, 2022, 11, 797-810.	1.0	4
9	Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age-related macular degeneration in daily clinical practice: data from the FRB! registry. Acta Ophthalmologica, 2022, 100, .	0.6	8
10	Characterization of Poor Visual Outcomes of Diabetic Macular Edema: The Fight Retinal Blindness! Project. Ophthalmology Retina, 2022, 6, 540-547.	1.2	3
11	INTERNATIONAL IMPACT OF THE COVID-19 PANDEMIC LOCKDOWN ON INTRAVITREAL THERAPY OUTCOMES. Retina, 2022, 42, 616-627.	1.0	11
12	Differences in Mean Values and Variance in Quantitative Analyses of Foveal OCTA Imaging. Klinische Monatsblätter Fur Augenheilkunde, 2022, 239, 513-517.	0.3	2
13	Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases. Ophthalmology Retina, 2022, 6, 1044-1053.	1.2	2
14	Genotype-phenotype spectrum in isolated and syndromic nanophthalmos. Acta Ophthalmologica, 2021, 99, e594-e607.	0.6	13
15	Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naïve neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 1463-1470.	1.0	10
16	Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry. Eye, 2021, , .	1.1	4
17	Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry. Acta Ophthalmologica, 2021, , .	0.6	4
18	Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy. Frontiers in Pharmacology, 2021, 12, 675295.	1.6	3

#	ARTICLE	IF	CITATIONS
19	Neovascular age-related macular degeneration: A review of findings from the real-world Fight Retinal Blindness! registry. <i>Clinical and Experimental Ophthalmology</i> , 2021, 49, 652-663.	1.3	15
20	Neovascular age-related macular degeneration at treatment intervals of 14 weeks or greater. <i>Clinical and Experimental Ophthalmology</i> , 2021, 49, 570-578.	1.3	2
21	Characterizing Flow and Structure of Diabetic Retinal Neovascularization after Intravitreal Anti-VEGF Using Optical Coherence Tomography Angiography: A Pilot Study. <i>Journal of Ophthalmology</i> , 2021, 2021, 1-16.	0.6	3
22	High-Throughput Sequencing to Identify Mutations Associated with Retinal Dystrophies. <i>Genes</i> , 2021, 12, 1269.	1.0	3
23	Thermal Laser Monotherapy for Extrafoveal Polypoidal Choroidal Vasculopathy. <i>Klinische Monatsblätter Für Augenheilkunde</i> , 2021, 238, 1299-1304.	0.3	0
24	FIVE-YEAR INCIDENCE AND VISUAL ACUITY OUTCOMES FOR INTRAVITREAL THERAPY IN BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2021, 41, 118-124.	1.0	7
25	ASSOCIATION BETWEEN ANATOMICAL AND CLINICAL OUTCOMES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR. <i>Retina</i> , 2021, 41, 1446-1454.	1.0	4
26	Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis. <i>Translational Vision Science and Technology</i> , 2021, 10, 5.	1.1	4
27	Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration from Two Regions. <i>American Journal of Ophthalmology</i> , 2020, 210, 116-124.	1.7	53
28	Outcomes of cataract surgery in eyes with diabetic macular oedema: Data from the Fight Retinal Blindness! Registry. <i>Clinical and Experimental Ophthalmology</i> , 2020, 48, 462-469.	1.3	9
29	Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2020, 127, 369-376.	2.5	16
30	SMOKING STATUS AND TREATMENT OUTCOMES OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2020, 40, 1696-1703.	1.0	5
31	Ranibizumab or Aflibercept for Diabetic Macular Edema. <i>Ophthalmology</i> , 2020, 127, 608-615.	2.5	42
32	ASSESSING THE ACCURACY OF A LARGE OBSERVATIONAL REGISTRY OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2020, 40, 866-872.	1.0	6
33	Prevalence and characteristics of macular atrophy in eyes with neovascular age-related macular degeneration. A study from a long-term observational dataset: the Fight Retinal Blindness! project. <i>British Journal of Ophthalmology</i> , 2020, 104, 1064-1069.	2.1	10
34	Lifetime Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2020, 138, 1234.	1.4	13
35	Intraocular Pressure Changes and Vascular Endothelial Growth Factor Inhibitor Use in Various Retinal Diseases: Long-Term Outcomes in Routine Clinical Practice. <i>Ophthalmology Retina</i> , 2020, 4, 861-870.	1.2	14
36	PREVALENCE AND RISK FACTORS FOR THE DEVELOPMENT OF PHYSICIAN-GRADED SUBRETINAL FIBROSIS IN EYES TREATED FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2020, 40, 2285-2295.	1.0	27

#	ARTICLE	IF	CITATIONS
37	Changes in real-world treatment patterns for diabetic macular oedema from 2009 to 2019 and 5-year outcomes: Data from the Fight Retinal Blindness! Registry. <i>Clinical and Experimental Ophthalmology</i> , 2020, 48, 802-812.	1.3	10
38	Four-week outcomes of vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration. <i>Clinical and Experimental Ophthalmology</i> , 2020, 48, 946-955.	1.3	1
39	A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion. <i>Eye</i> , 2020, 34, 1770-1796.	1.1	28
40	Outcomes of Suspending VEGF Inhibitors for Neovascular Age-Related Macular Degeneration When Lesions Have Been Inactive for 3 Months. <i>Ophthalmology Retina</i> , 2019, 3, 623-628.	1.2	31
41	Five-Year Real-World Outcomes of Occult and Classic Choroidal Neovascularization: Data From the Fight Retinal Blindness! Project. <i>American Journal of Ophthalmology</i> , 2019, 204, 105-112.	1.7	19
42	En Face Optical Coherence Tomography Imaging Ellipsoid Zone Regeneration in Laser-Induced and Solar Maculopathies. <i>Case Reports in Ophthalmological Medicine</i> , 2019, 2019, 1-8.	0.3	2
43	A Multicountry Comparison of Real-World Management and Outcomes of Polypoidal Choroidal Vasculopathy. <i>Ophthalmology Retina</i> , 2019, 3, 220-229.	1.2	16
44	Trainee-led versus specialist-led management of neovascular age-related macular degeneration: a registry-based study. <i>British Journal of Ophthalmology</i> , 2019, 103, 1158-1162.	2.1	1
45	Projection of Long-Term Visual Acuity Outcomes Based on Initial Treatment Response in Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2019, 126, 64-74.	2.5	22
46	MULTIMODAL IMAGING OF CHOROIDDAL LESIONS IN DISSEMINATED MYCOBACTERIUM CHIMAERA INFECTION AFTER CARDIOTHORACIC SURGERY. <i>Retina</i> , 2019, 39, 452-464.	1.0	14
47	Hif1a inactivation rescues photoreceptor degeneration induced by a chronic hypoxia-like stress. <i>Cell Death and Differentiation</i> , 2018, 25, 2071-2085.	5.0	29
48	Outcomes in Neovascular Age-Related Macular Degeneration when Neovascular Lesion Activity Is Uncertain: Observational Study. <i>Ophthalmology Retina</i> , 2018, 2, 531-538.	1.2	2
49	Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. <i>Progress in Retinal and Eye Research</i> , 2018, 65, 127-146.	7.3	205
50	Outcomes and Predictive Factors After Cataract Surgery in Patients With Neovascular Age-related Macular Degeneration. <i>The Fight Retinal Blindness! Project. American Journal of Ophthalmology</i> , 2018, 190, 50-57.	1.7	18
51	TWO YEAR OUTCOMES OF "TREAT AND EXTEND" INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2018, 38, 20-28.	1.0	83
52	THREE-DIMENSIONAL ANALYSIS OF SUBMACULAR PERFORATING SCLERAL VESSELS BY ENHANCED DEPTH IMAGING OPTICAL COHERENCE TOMOGRAPHY. <i>Retina</i> , 2018, 38, 1231-1237.	1.0	6
53	Early and Late Retinal Pigment Epithelium Tears after Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2018, 125, 237-244.	2.5	16
54	Review of people with retinal vasculitis and positive QuantiFERON®-TB Gold test in an area nonendemic for tuberculosis. <i>International Ophthalmology</i> , 2018, 38, 2389-2395.	0.6	8

#	ARTICLE	IF	CITATIONS
55	Clinical and social characteristics associated with reduced visual acuity at presentation in Australian patients with neovascular age-related macular degeneration: a prospective study from a long-term observational data set. The Fight Retinal Blindness! Project. <i>Clinical and Experimental Ophthalmology</i> , 2018, 46, 266-274.	1.3	4
56	Plasma levels of hypoxia-regulated factors in patients with age-related macular degeneration. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2018, 256, 325-332.	1.0	10
57	RANIBIZUMAB AND AFLIBERCEPT FOR THE TREATMENT OF PIGMENT EPITHELIAL DETACHMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2018, 38, 1954-1961.	1.0	6
58	Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2018, 125, 66-74.	2.5	73
59	Interdevice variability of central corneal thickness measurement. <i>PLoS ONE</i> , 2018, 13, e0203884.	1.1	13
60	Safety and Feasibility of a Novel Sparse Optical Coherence Tomography Device for Patient-Delivered Retina Home Monitoring. <i>Translational Vision Science and Technology</i> , 2018, 7, 8.	1.1	44
61	Outcome of Pediatric Cataract Surgeries in a Tertiary Center in Switzerland. <i>Journal of Ophthalmology</i> , 2018, 2018, 1-10.	0.6	9
62	The Proteomic Landscape in the Vitreous of Patients With Age-Related and Diabetic Retinal Disease. , 2018, 59, AMD31.		43
63	A pharmacoepidemiologic study of ranibizumab and aflibercept use 2013-2016. The Fight Retinal Blindness! Project. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2018, 256, 1839-1846.	1.0	13
64	Identification of novel diabetes impaired miRNA-transcription factor co-regulatory networks in bone marrow-derived Lin ⁻ /VEGF-R2 ⁺ endothelial progenitor cells. <i>PLoS ONE</i> , 2018, 13, e0200194.	1.1	7
65	Reply. <i>Ophthalmology</i> , 2018, 125, e33-e34.	2.5	1
66	Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, et al.: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials (<i>Ophthalmology</i> 2016;123:1751-1761). <i>Ophthalmology</i> , 2017, 124, e31-e32.	2.5	19
67	INCREASED INTRAOCULAR PRESSURE IS A RISK FACTOR FOR UNEXPLAINED VISUAL LOSS DURING SILICONE OIL ENDOTAMPONADE. <i>Retina</i> , 2017, 37, 2334-2340.	1.0	21
68	Clinical and Histopathologic Ocular Findings in Disseminated Mycobacterium chimaera Infection after Cardiothoracic Surgery. <i>Ophthalmology</i> , 2017, 124, 178-188.	2.5	40
69	<i>C2orf71</i> Mutations as a Frequent Cause of Autosomal-Recessive Retinitis Pigmentosa: Clinical Analysis and Presentation of 8 Novel Mutations. , 2017, 58, 3840.		13
70	Iris cyst in a child with Aicardi syndrome: a novel association. <i>Journal of AAPOS</i> , 2016, 20, 451-452.	0.2	1
71	Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2016, 100, 1640-1645.	2.1	36
72	METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2016, 36, 1418-1431.	1.0	145

#	ARTICLE	IF	CITATIONS
73	Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study. <i>Ophthalmology</i> , 2016, 123, 2545-2553.	2.5	59
74	Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2016, 123, 2393-2400.	2.5	47
75	Next generation sequencing based identification of disease-associated mutations in Swiss patients with retinal dystrophies. <i>Scientific Reports</i> , 2016, 6, 28755.	1.6	62
76	Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2016, 168, 1-12.	1.7	92
77	Two-Year Outcomes of "Treat and Extend" Intravitreal Therapy for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2015, 122, 1212-1219.	2.5	148
78	Time to Initial Clinician-Reported Inactivation of Neovascular Age-Related Macular Degeneration Treated Primarily with Ranibizumab. <i>Ophthalmology</i> , 2015, 122, 589-594.e1.	2.5	25
79	Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2015, 122, 1837-1845.	2.5	206
80	Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data. <i>British Journal of Ophthalmology</i> , 2015, 99, 359-364.	2.1	18
81	Reporting of harms by randomised controlled trials in ophthalmology. <i>British Journal of Ophthalmology</i> , 2014, 98, 1003-1008.	2.1	5
82	Comparison of Outcomes from a Phase 3 Study of Age-Related Macular Degeneration with a Matched, Observational Cohort. <i>Ophthalmology</i> , 2014, 121, 676-681.	2.5	41
83	Intravitreal Therapy in Bilateral Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2014, 121, 2073-2074.	2.5	13
84	EFFICIENT CAPTURE OF HIGH-QUALITY DATA ON OUTCOMES OF TREATMENT FOR MACULAR DISEASES. <i>Retina</i> , 2014, 34, 188-195.	1.0	104
85	Isolation and characterization of mouse bone marrow-derived Lin ^{hi} /VEGF-R2 ⁺ progenitor cells. <i>Annals of Hematology</i> , 2013, 92, 1461-1472.	0.8	5
86	Impact of Loading Phase, Initial Response and CFH Genotype on the Long-Term Outcome of Treatment for Neovascular Age-Related Macular Degeneration. <i>PLoS ONE</i> , 2012, 7, e42014.	1.1	34
87	Delayed Appearance of High Altitude Retinal Hemorrhages. <i>PLoS ONE</i> , 2011, 6, e11532.	1.1	33
88	Quantitative Analysis of OCT Characteristics in Patients with Achromatopsia and Blue-Cone Monochromatism. , 2006, 47, 1161.		63